<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165149</url>
  </required_header>
  <id_info>
    <org_study_id>17100205</org_study_id>
    <nct_id>NCT03165149</nct_id>
  </id_info>
  <brief_title>Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding</brief_title>
  <official_title>Effect of a Topical Ketamine on Acute and Chronic Post-mastectomy Pain, Dose Finding - Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of addition of different doses of Ketamine&#xD;
      locally in acute and chronic post-mastectomy pain after breast cancer surgery and on the&#xD;
      probability of developing chronic post-mastectomy pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the total amount of morphine consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>total amount of rescue analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain intensity</measure>
    <time_frame>48 hours</time_frame>
    <description>pain intensity measured by Visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group (A)</intervention_name>
    <description>patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.</description>
    <arm_group_label>Group (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group (B)</intervention_name>
    <description>patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.</description>
    <arm_group_label>Group (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group (c)</intervention_name>
    <description>patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.</description>
    <arm_group_label>Group (C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - American society of heart association class I-II female patients&#xD;
&#xD;
          -  aged 18-60 years&#xD;
&#xD;
          -  scheduled for modified radical mastectomy with axillary dissection for breast&#xD;
             carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to the study drugs&#xD;
&#xD;
          -  significant cardiac-&#xD;
&#xD;
          -  respiratory-&#xD;
&#xD;
          -  renal or hepatic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Egypt Cancer Instuite</name>
      <address>
        <city>Assuit</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Fatma Adel El sherif,MD</investigator_full_name>
    <investigator_title>lecturer of anesthesia, ICU and pain releif</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

